Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | GLS | O94925 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476083 | 1.00 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4468251 | 1.00 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL21901972 | 0.92 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL2319856 | 0.90 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL9761279 | 0.90 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL25302148 | 0.90 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL9761288 | 0.90 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL644937 | 0.90 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL23077378 | 0.90 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL12439955 | 0.90 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2416780-B1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2416781-B1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2417146-B1 | (2'-DEOXY-RIBOFURANOSYL)-1,3,4,7-TETRAHYDRO-(1,3)DIAZEPIN-2-ONE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130116207-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116207-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8329665-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010118010-A1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118006-A1 | (2 ' -DEOXY-RIBOFURANOSYL) -1,3,4, 7-TETRAHYDRO- (1,3) IAZEPIN-2-0NE DERIVATIVES FOR TREATING CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118013-A1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-5556968-A | Polyazamacrocycle chelating agents with amide linkages | NYCOMED SALUTAR, INC. (US) | 1996-09-17 | — | — | US | disclosed |
| EP-0556240-A1 | CHELATING AGENTS. | COCKBAIN JULIAN R M (GB) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992008707-A1 | CHELATING AGENTS | COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | RNASE1, UNG, HCCS | CASP3 29/4885CA12 373/4885CA9 92/4885 |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | CASP3 29/4885CA12 373/4885CA9 92/4885 |
| US-20130116207-A1 | Compositions and Methods for Treating Cancer | RNASE1, UNG, HCCS | CASP3 29/4885CA12 373/4885CA9 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.